Afya (AFYA) – Investment Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Afya (NASDAQ: AFYA) in the last few weeks:

• 1/10/2026 – Afya was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 1/9/2026 – Afya was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 1/8/2026 – Afya had its price target lowered by analysts at UBS Group AG from $19.00 to $18.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Afya had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $22.00 price target on the stock, down previously from $24.50.
• 12/20/2025 – Afya was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/15/2025 – Afya was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.